erlotinib hydrochloride has been researched along with Malignant Melanoma in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ermolovich, T; Hemperly, S; Lountzis, NI; Purcell, SM; Sheikh, HA | 1 |
| Baranyi, M; Berger, W; Donia, M; Garay, T; Grusch, M; Hegedűs, B; Molnár, E; Rittler, D; Tímár, J | 1 |
| Eichenfield, DZ; Orme, CM; Seidman, JS | 1 |
| Boespflug, A; Kaya, A; Kaya, G; Saurat, JH; Saxer-Sekulic, N; Sorg, O; Thomas, L | 1 |
| Li, W; Zhou, Y | 1 |
| Blanchet, B; Boudou-Rouquette, P; Dupin, N; Goldwasser, F; Mortier, L; Sakji, L; Thomas-Schoemann, A; Vidal, M; Zhen, Y | 1 |
| Dahlman, KB; Greco, FA; Hainsworth, JD; Johnson, DB; Kelley, MC; Mudigonda, TV; Puzanov, I; Sosman, JA; Spigel, DR; Wyman, K | 1 |
| Deng, WG; Ekmekcioglu, S; Grimm, EA; Kwon, J; Poindexter, NJ | 1 |
| Bardelli, A; Beijersbergen, RL; Bernards, R; Di Nicolantonio, F; Huang, S; Prahallad, A; Salazar, R; Sun, C; Zecchin, D | 1 |
| Juergens, R; Levine, MN | 1 |
| Lo, RS | 1 |
| Bahleda, R; Blay, JY; Dieras, V; LoRusso, P; Macaulay, VM; Mery-Mignard, D; Middleton, MR; Protheroe, AS; Sessa, C; Soria, JC; Tolcher, A | 1 |
2 trial(s) available for erlotinib hydrochloride and Malignant Melanoma
| Article | Year |
|---|---|
A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Erlotinib Hydrochloride; Humans; Melanoma; Neoplasm Metastasis; Treatment Outcome | 2016 |
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Melanoma; Middle Aged; Quinazolines; Receptor, IGF Type 1; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2013 |
10 other study(ies) available for erlotinib hydrochloride and Malignant Melanoma
| Article | Year |
|---|---|
Darkening and eruptive nevi during treatment with erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Melanoma; Nevus, Pigmented; Protein Kinase Inhibitors; Skin Neoplasms | 2019 |
Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression.
Topics: Adult; Aged; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Melanoma; Middle Aged; Mutation; Neoplasm Proteins; Phenotype; Proto-Oncogene Proteins B-raf; RNA, Messenger; Signal Transduction; Time Factors; Vemurafenib | 2019 |
Nevoid melanoma and eruptive nevi from erlotinib.
Topics: Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Melanoma; Nevus; Protein Kinase Inhibitors; Skin Neoplasms | 2020 |
RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH.
Topics: Antineoplastic Agents; Chloracne; Cytochrome P-450 CYP1A1; Dioxins; Drug Eruptions; Enzyme Activation; Epidermal Cyst; Erlotinib Hydrochloride; Female; Gefitinib; Hep G2 Cells; Humans; Male; Melanoma; Protein Kinase Inhibitors; Skin Neoplasms; Vemurafenib | 2018 |
LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial-mesenchymal transition.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hypoxia; MAP Kinase Signaling System; Melanoma; Membrane Glycoproteins; Neoplasm Invasiveness; Neovascularization, Pathologic; Up-Regulation | 2019 |
An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Monitoring; Erlotinib Hydrochloride; Humans; Indoles; Liquid-Liquid Extraction; Melanoma; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Vemurafenib | 2013 |
IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.
Topics: Apoptosis; Apoptotic Protease-Activating Factor 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Interleukins; Melanoma; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Signal Transduction | 2011 |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Gefitinib; HEK293 Cells; Humans; Indoles; Melanoma; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; RNA Interference; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents | 2012 |
Receptor tyrosine kinases in cancer escape from BRAF inhibitors.
Topics: Animals; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Melanoma; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor Protein-Tyrosine Kinases; Sulfonamides; Transplantation, Heterologous; Vemurafenib | 2012 |